Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.

被引：0

作者：

de Witte, T ^{[1
]}

Hagemeijer, A ^{[1
]}

Suciu, S ^{[1
]}

Delforge, M ^{[1
]}

Jotterand-Bellomo, M ^{[1
]}

Tigaud, I ^{[1
]}

Belhabri, A ^{[1
]}

Aul, C ^{[1
]}

Avaido, M ^{[1
]}

Schouten, H ^{[1
]}

Ferrant, A ^{[1
]}

Amadori, S ^{[1
]}

Muus, P ^{[1
]}

Anak, O ^{[1
]}

Beeldens, F ^{[1
]}

Jansen, J ^{[1
]}

Hellstrom-Lindberg, E ^{[1
]}

Gratwohl, A ^{[1
]}

Willemze, R ^{[1
]}

机构：

[1] Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

来源：

BLOOD | 2001年 / 98卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2595

引用

页码：619A / 620A

页数：2

共 20 条

[1] Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups
de Witte, T
Hagemeijer, A
Suciu, S
Delforge, M
Jotterand-Bellomo, M
Tigaud, I
Belhabri, A
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, O
Beeldens, F
Jansen, J
Hellstrom-Lindberg, E
Gratwohl, A
Willemze, R
BONE MARROW TRANSPLANTATION, 2002, 29 : S55 - S55
[2] The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation:: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
de Witte, T
Suciu, S
van Dijk, J
Delforge, M
Hagemeijer, A
Jotterand-Bellomo, M
Tigaud, I
Belhabri, A
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, Ö
Gratwohl, A
Willemze, R
BLOOD, 2000, 96 (11) : 546A - +
[3] Autologous stem cell transplantation for patients with poor risk MDS and secondary AML (sAML). A joint study of the EORTC, EBMT, SAKK and GIMEMA leukemia groups.
DeWitte, T
Suciu, S
Verhoef, G
Labar, B
Archimbaud, E
Aul, C
Selleslag, D
Ferrant, A
Wijermans, P
Mandelli, F
Amadori, S
Jehn, U
Muus, P
DeMuynck, H
Dardenne, M
Zittoun, R
Willemze, R
Gratwohl, A
Apperley, J
BLOOD, 1997, 90 (10) : 2594 - 2594
[4] The impact of post-remission therapy on outcome of patients with poor-risk AIDS and secondary AML treated with intensive chemotherapy with or without stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAK, HOVON, Scandinavian, and the Gimema leukemia groups.
De Witte, TM
Hagemeijer, A
Suciu, S
Belhabri, A
Delforge, M
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Biersack, H
Ferrant, A
Kovacsovics, T
Muus, P
Jansen, J
Beeldens, F
Gratwohl, A
Hess, U
Helström-Lindberg, E
Wijermans, P
Ossenkoppele, G
Marie, JP
Willemze, R
Amadori, S
BLOOD, 2003, 102 (11) : 185A - 185A
[5] The impact of the presence of an HLA-identical donor on the prognosis of patients with high risk MDS and AML following MDS treated with an intensive antileukemic therapy: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
Oosterveld, M
de Witte, T
Suciu, S
Verhoef, G
Labar, B
Belhabri, A
Schouten, H
Aul, C
Runde, V
Ferrant, A
Selleslag, D
Amadori, S
Jehn, U
Muus, P
Anak, O
Marie, JP
Willemze, R
Gratwohl, A
Niederwieser, D
BLOOD, 2000, 96 (11) : 357B - 357B
[6] A new prognostic disease specific model to predict survival after intensive antileukemic treatment for young patients with poor-risk MDS and AML: Results of the CRIANT and AML-10 studies conducted by the EORTC/GIMENA/SAKK/HOVON/EBMT groups.
Oosterveld, M
Suciu, S
Muus, P
Delforge, M
Belhabri, A
Aul, C
Selleslag, D
Ferrant, A
Marie, JP
Amadori, S
Jehn, U
Hess, U
Willemze, R
Hellstrom-Lindberg, E
Vignetti, M
Labar, B
Mandelli, F
De Witte, T
BLOOD, 2004, 104 (11) : 557A - 557A
[7] Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups
de Witte, T
Hagemeijer, A
Suciu, S
Belhabri, A
Delforge, M
Aul, C
Aivado, M
Selleslag, D
Schouten, H
Ferrant, A
Biersack, H
Amadori, S
Muus, P
Jehn, U
Beeldens, F
Jansen, J
Hellstrom-Lindberg, P
Ossenkoppele, G
Gratwohl, A
Marie, JP
Willemze, R
BONE MARROW TRANSPLANTATION, 2006, 37 : S1 - S1
[8] The prognostic impact of cytogenetic features and clonality of patients with poor risk MDS and secondary AML (sAML) after treatment with intensive chemotherapy and stem cell transplantation for the treatment; a joint study of the EORTC, EBMT, SAK, HOVO
de Witte, T
Suciu, S
Delforge, M
Hagemeijer, A
Jotterrand-Bellomo, M
Tigaud, I
Belhabi, A
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, O
Gratwohl, A
Willemze, R
van Dijk, J
BONE MARROW TRANSPLANTATION, 2001, 27 : S255 - S255
[9] Intensive chemotherapy followed by stem cell transplantation for patients with poor-risk mds and secondary AML (sAML).
De Witte, T
Suciu, S
Verhoef, G
Labar, B
Archimbaud, E
Aul, C
Selleslag, D
Ferrant, A
Wijermans, P
Mandelli, F
Amadori, S
Jehn, U
Muus, P
DeMuynck, H
Dardenne, M
Zittoun, R
Willemze, R
Gratwohl, A
Apperley, J
BLOOD, 1998, 92 (10) : 714A - 714A
[10] Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project.
deWitte, TM
Suciu, S
Anak, O
Hagemeijer, A
Selleslag, D
Ferrant, A
Delforge, M
Belhabi, A
Schouten, H
Gratwohl, A
Aul, C
Aivado, M
Amadori, S
Muus, P
Tigaud, I
Jotterand-Bellomo, M
Willemze, R
BLOOD, 1999, 94 (10) : 382B - 382B

← 1 2 →